CA-DEGREED
23.6.2022 21:15:12 CEST | Business Wire | Press release
Degreed , the global innovator in professional lifelong learning chosen by more than one in three Fortune 50 companies, today announced the acquisition of talent academy platform, Learn In , and the return of Co-founder David Blake as CEO. Blake was previously the Co-founder and CEO of Learn In.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005917/en/
Learn In helps companies establish internal talent academies that bring together all the resources needed for building a highly skilled workforce, including the longer journey of developing deep skills. Learn In’s core features supplement those of the category-defining Degreed LXP (Learning Experience Platform), including a prepaid learning stipend card, a world-class skills marketplace and custom program builder, a tuition benefits manager, and dedicated coaching.
“A corporate capability academy goes beyond ‘a library of content,’” said global industry analyst and CEO of the Josh Bersin Company, Josh Bersin . “It’s a place people go to advance their job-related capabilities. It goes beyond technical and functional skills and focuses on the real business capabilities a company needs to thrive.”
Degreed plus Learn In will unify the broader range of development options people use, spanning daily learning to long-term upskilling for individual career growth and innovation within organizations.
Blake’s plans for the future of Degreed were divergent with the current direction, so an amicable decision was made that he return to the company as CEO and execute that vision.
Degreed thanks Dan Levin for the progress he has driven and his stewardship of the Degreed mission over the past 15 months, and is grateful for his accomplishments, including increasing our client base, establishing operational rigor for scale, and significantly expanding our partner ecosystem and overall global footprint.
“Businesses that can quickly build effective talent are the ones that will be able to deliver on strategic business goals,” said David Blake, Co-founder and CEO of Degreed . “Just as Degreed created the LXP market, Learn In has begun for talent academies. Now together, we have the product and technology to help our customers deliver business capabilities at scale with continued innovation in the learning and skills space.”
“At BMO, our strategy is to build a digitally-enabled bank that’s ready for the future. This means we need to equip employees with the skills they need for their job, their career, for the future of work, and as they follow their personal passions,” says Gina Jeneroux, Chief Learning Officer at BMO Financial Group . “As Degreed and Learn In come together, it will offer a more integrated opportunity for organizations like ours to engage employees and build a broader range of skills—from curious, ‘in-the-moment’ learning through to deeper reskilling and credentials.”
This is the fourth acquisition for Degreed, and Blake re-joins a seasoned Degreed leadership team from Bank of America, Mastercard, Danone, LinkedIn, Adobe, SAP and Saba.
About Degreed
Degreed empowers innovation through learning. As a changemaker on a global scale, we work with one in three Fortune 50 companies to spark a culture of learning across their enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need – through individual, collaborative and experiential modes of learning – to drive individual and business results. Founded in 2012, Degreed is headquartered in Pleasanton, California, with users spanning 191 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
About Learn In
Learn In helps companies establish talent academies that steer all the resources needed for building a highly skilled workforce. HR, Talent and L&D leaders use Learn In to modernize access to learning budgets and world-class programs, and to simplify the delivery of custom programs to employee groups. Learn In’s core features include a tuition benefits manager, a prepaid learning stipend card, a world-class program marketplace and custom program builder, and dedicated coaching. Now every employee can build deeper skills precisely aligned to company needs. Co-founded by the founders of Degreed, Learn In is backed by leading edtech & future-of-work investors, including Firework Ventures, Kickstart Fund, Album, GSV, and Village Global, and has been covered in CNBC, USA Today, EdTechReview, EdSurge, Fast Company, and Techcrunch.
Learn more about Learn In: Website | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005917/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom